Incyte Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ICY.F | 6IB.F | 9969.HK | IOVA | 1530.HK | GMAB | |
|---|---|---|---|---|---|---|
| Market cap | 22.13B | 17.27B | 21.56B | 3.94B | 37.99B | 33.89B |
| P/E (TTM) | 62.7 | 123.8 | 20.3 | — | 4.1 | 43.4 |
| Forward P/E | 24.6 | — | 53.2 | -44.4 | 11.2 | 34.9 |
| Price/book | 4.4 | 6.2 | 1.9 | 5.4 | 1.2 | 5.5 |
| Dividend yield | — | — | — | — | 1.69% | — |
| 1-year change | +15.09% | −7.55% | −14.61% | +387.85% | −51.32% | +90.20% |
| Today | +4.83% | +3.42% | +1.33% | −1.47% | +4.00% | −0.72% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ICY.F news ›Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Incyte to present 30+ ASH 2026 abstracts, including INCA033989 myelofibrosis and ET data and latarcibart VWD results, plus an investor… Plus members following INCY got this by push and email at 09:00:01 ET - 1.7s after publication. Incyte…
Chronic Hand Eczema Pipeline Analysis 2026: Phase III and Phase II Assets, MOA Breakdown, and Route of Administration Trends | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics
Albany New York November 03 2026 As per DelveInsight s assessment globally Chronic Hand Eczema pipeline constitutes 5 key companies continuously working towards developing 5 Chronic Hand Eczema treatment therapies analysis of Clinical…
Major Depressive Disorder Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm
Major Depressive Disorder Pipeline 2026: Key Companies, MOA, openPR.com Major Depressive Disorder Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis…
Incyte raises sales outlook as quarterly revenue reaches US$1.56B
Opzelura and hematology sales drove the forecast increase, while a US$1.23 billion acquisition charge lifted research expense. Revenue grew 14 per cent to US$1.56 billion as Incyte Corporation NASDAQINCY raised its full-year sales forecast…
Incyte: Upgrading To Hold After ESMO Closed The Valuation Gap
(NASDAQ:INCY) Seeking Alpha - I upgraded Incyte to Hold, with a fair value of $112.19 per share, now just 4% below the market price. - ESMO Phase 1 data for KRAS G12D and TGFβR2×PD-1 support higher approval probabilities. - Q3 net sales r
Incyte Corporation $INCY Stock: Profund Advisors LLC Raises Stake
Posted by Michael Walen on Nov 2nd, 2026 Here are the key news stories impacting Incyte this week: INCY stock opened at $120.39 on Monday. The company has a market cap of $24.54 billion, a P/E ratio of 64.04, a price-to-earnings-growth…
Incyte Reports $1.56 Billion in Q3 Revenue; Raises 2026 Net Sales Guidance
TradingView Incyte Reports $1.56 Billion in Q3 Revenue; Raises 2026 Net Sales Guidance Incyte reported third-quarter 2026 revenue of $1.56 billion, up 14% year over year, while GAAP results included a $784.8 million net loss
Incyte, Genmab to Test Drug Combination for Colorectal Cancer
WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) and Genmab A/S (Nasdaq: GMAB) have agreed to jointly support an early-stage clinical trial combining two experimental cancer drugs with chemotherapy, expanding their efforts to develop a…
More from 1 other outlet
Incyte, Genmab Pair Therapies in KRAS G12D Colorectal Cancer Trial
GenomeWeb Incyte, Genmab Pair Therapies in KRAS G12D Colorectal Cancer Trial
Incyte Corp (INCY) Q3 2026 Earnings Call Highlights: Revenue Up 14% as Core Business Surges 30% and Guidance Raised
Incyte Corp (INCY) Q3 2026 Earnings Call Highlights: Revenue Up GuruFocus Release Date: October 29, 2026 Q: What is the potential opportunity for Opzelura in mild-to-moderate hidradenitis suppurativa? A: CEO William Meury said there is no…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com10
- themarketsdaily.com8
- theglobeandmail.com7
- seekingalpha.com5
- forbes.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 58 articles, not a forecast.